Haemonetics Corp.
HAE
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.54B
Close$
$126.27
63.1% upside
Current Fair Value
63.1% upsideUndervalued by 63.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.54 Billion |
|---|---|
| Enterprise Value | $4.52 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.05 |
| Beta | 0.52 |
| Outstanding Shares | 46,224,000 |
Return
| Return on Equity | 10.89% |
|---|---|
| Return on Assets | 4.06% |
| Return on Invested Capital | 7.23% |
Valuation & Multiples
| P/E Ratio | 38.17 |
|---|---|
| PEG | -28.32 |
| Price to Sales | 2.76 |
| Price to Book Ratio | 4.07 |
| Enterprise Value to Revenue | 3.39 |
| Enterprise Value to EBIT | 29.56 |
| Enterprise Value to Net Income | 46 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 1.37 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$1.28
Average shareholder expectationRevenue Estimate
$337.03 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$1.07
Average shareholder expectationRevenue Estimate
$327.89 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 42.55% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.53%▼ 96.25% |
|---|---|
| Total Invested | $187.88M▼ 92.99% |
| Investors Holding | 42▼ 290.00% |
ESG Score
No data
About Haemonetics Corp.
CEO: Christopher Simon